Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Lowered by StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a report issued on Friday.

A number of other equities research analysts also recently weighed in on TEVA. Barclays cut their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Piper Sandler lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research note on Friday, January 17th. UBS Group decreased their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a research report on Thursday, January 30th. Finally, Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, March 6th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA traded up $1.47 on Friday, reaching $16.14. 20,887,815 shares of the company traded hands, compared to its average volume of 12,987,501. The stock has a market capitalization of $18.29 billion, a PE ratio of -11.13, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company's 50 day moving average is $18.70 and its 200-day moving average is $18.35. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts anticipate that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the sale, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.55% of the stock is owned by corporate insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds and other institutional investors have recently modified their holdings of TEVA. Diversify Advisory Services LLC increased its position in Teva Pharmaceutical Industries by 2.5% in the fourth quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company's stock worth $426,000 after purchasing an additional 496 shares during the period. Sanctuary Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 1.9% during the 3rd quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company's stock worth $601,000 after buying an additional 664 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of Teva Pharmaceutical Industries by 0.3% during the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company's stock worth $4,964,000 after buying an additional 699 shares during the last quarter. Townsquare Capital LLC lifted its holdings in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after buying an additional 812 shares during the period. Finally, Metis Global Partners LLC boosted its stake in Teva Pharmaceutical Industries by 6.7% in the fourth quarter. Metis Global Partners LLC now owns 13,697 shares of the company's stock valued at $302,000 after acquiring an additional 860 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.